#United States #Minneapolis #Bio-Techne #ESR1 #Asuragen

Bio-Techne Unveils New ESR1 Mutation Monitoring Assay

Bio-Techne Corporation, traded on NASDAQ as TECH, has unveiled an innovative research-use-only assay called the ESR1 mutation monitoring assay. Developed under the Asuragen brand, this highly sensitive tool is designed to detect mutations in the ESR1 gene, which are significantly associated with hormone receptor-positive (HR+) metastatic breast cancer. The launch was officially announced on December 10, 2024, and the product will be prominently showcased at the San Antonio Breast Cancer Symposium.

A Significant Development in Cancer Monitoring

The detection of ESR1 mutations is crucial as these mutations can occur in up to 40% of HR+ metastatic breast cancer patients following treatment with endocrine therapies. Early identification of these mutations can empower clinicians to recognize potential treatment resistance, thus enabling timely changes to patient management strategies. Unfortunately, many existing molecular testing methods do not have the sensitivity or reliability to detect these mutations effectively, presenting a gap in cancer care that the new assay aims to fill.

The ESR1 mutation monitoring assay comprises two key components: the QuantideX® qPCR ESR1 exoMutation Kit and the ExoLution™ Plus cfDNA + exoRNA Isolation Kit. This innovative approach allows the assay to detect 11 specific ESR1 mutations with exceptional sensitivity, providing a much-needed solution for clinical research laboratories.

Advantages of the ESR1 Mutation Assay

What sets this assay apart from existing technologies is its capability to operate with standard qPCR methods, which facilitates seamless integration into current laboratory workflows without the burden of investing in specialized equipment. By tapping into the molecular signals derived from both cell-free DNA and exosomal RNA, the assay achieves levels of sensitivity previously reserved for more complex and costly technologies.

Dr. Matt McManus, president of Bio-Techne's Diagnostics and Spatial Biology Segment, emphasized the importance of this innovation, stating, "With the increasing number of potential medications targeting ESR1 mutations in clinical trials, it’s imperative for laboratory scientists to detect these mutations. Our assay not only offers high sensitivity but also convenience for lab personnel."

Implications for Future Cancer Treatment

As the landscape of breast cancer therapy evolves with new drug developments, the capability to monitor ESR1 mutations closely becomes more critical. The tailored treatment of HR+ metastatic breast cancer can potentially improve, leading to better patient outcomes through timely adjustments in therapeutic approaches based on mutation status.

For those interested in a deeper dive into this product, additional details are available on Asuragen's official website. It is essential to note that this assay is intended solely for research applications and is not validated for diagnostic use.

About Bio-Techne Corporation

Bio-Techne Corporation is a leading entity in the life sciences industry, dedicated to propelling advancements in research and clinical diagnostics. With a vast array of products that cater to scientific inquiries into cellular functions and disease progress, Bio-Techne has made substantial contributions to drug discovery and clinical testing. In fiscal 2024, the company reported impressive net sales nearing $1.2 billion, supported by a dedicated workforce of about 3,100 employees. For more information about Bio-Techne and its wide range of innovative products, visit their official website or connect via popular social media platforms.

In conclusion, the introduction of the ESR1 mutation monitoring assay marks a significant advancement in the realm of breast cancer treatment, providing essential tools for early detection and better management of patient care.